Sustained release tablet containing beta-nicotinamide mononucleotide and coenzyme Q10 and preparation method thereof

By using different models of hydroxypropylmethylcellulose combination to prepare sustained release tablets of β-nicotinamide single nucleotide and Coenzyme Q10, the gastrointestinal adverse reactions and process complexity in the prior art were solved, and the drug was stabilized Release and cost reduction improve drug compliance and product stability.

CN119015241APending Publication Date: 2024-11-26VISUM PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310606119.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The disintegration of existing single or compound preparations of β-nicotinamide single nucleotide and Coenzyme Q10 in the stomach leads to adverse gastrointestinal reactions. The sustained-release preparations are complex in the process and costly, making it difficult to ensure the stability and taste of the drug.

Method used

Using a mixture of different models of hydrophilic gel sustained-release framework materials, hydroxypropylmellose K4MCR and hydroxypropylmellose K100LVCR, the sustained-release tablets are prepared through dry granulation process to form a hydrated gel layer to control drug release and avoid Peaks and valleys and reduce production costs.

Benefits of technology

The smooth release of β-nicotinamide single nucleotide and coenzyme Q10 is achieved, avoiding fluctuations in blood drug concentration, reducing the frequency of drug use, improving drug compliance, and significantly reducing product production and use costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004250618470000031
    Figure BDA0004250618470000031
  • Figure BDA0004250618470000041
    Figure BDA0004250618470000041
  • Figure BDA0004250618470000042
    Figure BDA0004250618470000042
Patent Text Reader

Abstract

The invention belongs to the field of medicine / health-care preparations, and provides a sustained-release tablet containing beta-nicotinamide mononucleotide and coenzyme Q10 and a preparation method of the sustained-release tablet. The sustained release material in the sustained release tablet is a mixture of hydroxypropyl methylcellulose K4MCR and hydroxypropyl methylcellulose K100LVCR; the preparation method adopts dry granulation. The sustained release tablet disclosed by the invention has the beneficial effect of long-acting release, the medication frequency is reduced, and the compliance of users is improved. The dry granulation product is short in development period, simple in process and good in preparation reproducibility, and the medication cost of users can be effectively reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine / health care preparations, and specifically relates to a sustained-release tablet containing β-nicotinamide mononucleic acid and coenzyme Q10 and a preparation method thereof. Background Art

[0002] β-Nicotinamide mononucleotide (NMN) is a synthetic substrate of coenzyme I (NAD+) and a derivative of nicotinic acid. Nicotinic acid is an essential vitamin for the human body. Nicotinic acid exists in the form of nicotinamide in the body and is converted into coenzyme I in the human body. It plays a role in many biological redox reactions. Almost all physiological activities are related to coenzyme I, including energy metabolism, gene stability, neurotransmission, metabolism, etc. The level of NMN and the activity of nicotinamide nucleotide adenosyltransferase (NAMPT) in the body directly affect the concentration of NAD. At the same time, NMN directly participates in the transfer of adenosine in the body and is an important synthetic substrate and functional substance in the body. NMN has the effects of anti-aging, enhancing immunity, and treating cardiovascular and cerebrovascular diseases. At the same time, NMN also regulates the secretion of insulin and affects the expression level of mRNA.

[0003] Coenzyme Q10 is a fat-soluble natural vitamin substance that exists in many organisms. Its structure is similar to that of vitamin K and is one of the important elements that humans cannot do without. The content of coenzyme Q10 in the human body is 0.5-1.5g, and it is distributed more in the heart, liver, kidneys and pancreas. With the increase of age, the content of coenzyme Q10 in the human body will decrease and need to be supplemented from the outside. Lack of coenzyme Q10 may be the primary cause of myocardial dysfunction heart disease. Coenzyme Q10 is an important antioxidant that can inhibit the formation and development of atherosclerosis.

[0004] Currently, most of the single preparations of β-nicotinamide mononucleotide or coenzyme Q10 on the market are immediate-release tablets or capsules. After oral administration, the immediate-release dosage form generally disintegrates in the stomach, and the drug components are released. The released drug components enter the intestine and are absorbed by the intestine, and then reach the site of action, thereby producing the corresponding therapeutic effect. The disintegration process in the stomach can easily cause the local concentration of β-nicotinamide mononucleotide or coenzyme Q10 in the stomach to be too high, causing adverse gastrointestinal reactions such as nausea and vomiting.

[0005] The main feature of sustained-release preparations is that they can provide the human body with an appropriate blood drug concentration within a specific period of time as needed, and can also maintain this blood drug concentration for a longer period of time while reducing the number of dosing times. When taking ordinary preparations, the blood drug concentration generally rises quickly and falls relatively quickly. In order to achieve the blood drug concentration required for treatment, it is necessary to increase the number of dosing times. Repeated dosing will cause peak and valley phenomena, while sustained-release preparations avoid these situations and increase the adaptability of medication. Compared with ordinary preparations, sustained-release preparations also have the characteristics of improving patient compliance with medication. For example, the concentration of skeleton-type sustained-release drugs in contact with the gastrointestinal mucosa is relatively low, thus reducing the irritation of some drugs to the gastrointestinal tract, thereby preventing adverse reactions such as vomiting and nausea. For drugs with a short half-life, the number of medications should be reduced and medication should be avoided at night.

[0006] The compound sustained-release preparation of β-nicotinamide mononucleotide and coenzyme Q10 can not only achieve a wider range of therapeutic or health-care effects than single-prescription preparations, but also avoid the peak-valley phenomenon caused by fluctuations in blood drug concentrations, reduce the frequency of use of the drug users, and improve compliance. In addition, the dry granulation equipment and process are relatively simple, and the production cycle is shortened, which can effectively reduce the labor and equipment costs of product production, bringing good news to the majority of drug users.

[0007] Among the invention patents that have been published so far, the patents involving compound preparations of β-nicotinamide mononucleotide and coenzyme Q10 are as follows:

[0008] The patent document with publication number CN112933058A (applicant: Baolihua (Nanjing) Pharmaceutical Co., Ltd.) uses β-nicotinamide mononucleotide as the raw material and polyvidone K30 ethanol solution as the binder for wet granulation, and fluidized bed drying process is used to prepare β-nicotinamide mononucleotide sustained-release tablets. In particular, ethanol is volatile, and its fluidized bed drying temperature is 60°C. Its EHS risk cannot be ignored, and the raw material has poor stability at this temperature; and the wet granulation process is more complicated than the dry granulation process, and it is difficult to truly reduce the cost of medication.

[0009] Patent document with publication number CN112137977A (applicant: Shenzhen Wujian Technology Co., Ltd.) prepares sustained-release enteric orally disintegrating tablets including at least one of nicotinamide mononucleotide, curcumin, coenzyme Q10 or folic acid, and the preparation method thereof is to prepare pellets by hot melt extrusion, enteric coating by fluidized bed, mix the enteric coated pellets with excipients, and compress the tablets. Coenzyme Q10 has poor stability and is unstable in light, acidic, alkaline, high temperature, and oxidative environments. Therefore, the quality of coenzyme Q10 cannot be guaranteed by preparing pellets by hot melt extrusion. Orally disintegrating tablets require good taste, that is, the particle size should be below 0.15mm to 0.2mm after oral disintegration. The hot melt extrusion is cut to obtain pellets with a diameter of 0.3mm to 0.8mm. After enteric coating, the diameter of the enteric coated pellets will be further increased, so that the taste cannot be guaranteed, and there will even be a sense of gravel after taking. The enteric coating of functional pellets is easily damaged during tableting, and its functionality is reduced. In summary, the activity of the raw materials of the sustained-release enteric-coated orally disintegrating tablets prepared in this patent document cannot be guaranteed, the process requirements are high and the taste cannot be guaranteed.

[0010] Therefore, it is of obvious advantage to develop a sustained-release compound preparation of β-nicotinamide mononucleotide and coenzyme Q10 that is affordable and has guaranteed efficacy.

[0011] Dry granulation refers to a method in which the drug powder is mixed, directly pressed into tablets using appropriate equipment, and then broken into particles of the required size. The dry granulation process is simple, time-saving, and energy-saving, and can effectively reduce the production cost of the product.

[0012] Using only one type of hydrophilic gel sustained-release matrix material, hypromellose, cannot control the release of drugs well. Using different types of hypromellose in combination can maintain a stable release process, effectively avoid fluctuations in blood drug concentration, avoid peak and valley phenomena, reduce the frequency of use of the drug users, and improve compliance. Summary of the invention

[0013] In view of the problems existing in the above-mentioned prior art, the present invention provides a compound sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, using different types of hydrophilic gel sustained-release skeleton materials, hydroxypropyl methylcellulose K4MCR and hydroxypropyl methylcellulose K100LVCR, wherein the high-viscosity hydroxypropyl methylcellulose K4MCR forms a hydrated gel layer at a slower speed and can maintain release for a longer time, and the low-viscosity hydroxypropyl methylcellulose K100LVCR forms a hydrated gel layer at a faster speed, which can ensure the release of the drug in the early stage of medication. The two are mixed and used to maintain a stable release process of the drug and achieve a sustained-release effect. The preparation method adopts a simple dry granulation process, and the produced compound sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10 has obvious therapeutic effect and cost advantages.

[0014] The technical solution adopted by the present invention is:

[0015] A sustained-release tablet containing beta-nicotinamide mononucleotide and coenzyme Q10. The sustained-release material in the sustained-release tablet is a mixture of hypromellose K4MCR and hypromellose K100LVCR. The preparation method adopts dry granulation.

[0016] Preferably, the weight ratio of the hypromellose K4MCR to the hypromellose K100LVCR is 1:1 to 1:5.

[0017] Preferably, the weight ratio of the hypromellose K4MCR to the hypromellose K100LVCR is 1:1 or 1:5.

[0018] When the weight ratio of hydroxypropyl methylcellulose K4MCR and hydroxypropyl methylcellulose K100LVCR is 1:1, a long-acting release of 24 hours can be achieved; when the weight ratio of hydroxypropyl methylcellulose K4MCR and hydroxypropyl methylcellulose K100LVCR is 1:5, a long-acting release of 12 hours can be achieved.

[0019] More preferably, the weight ratio of hypromellose K4MCR to hypromellose K100LVCR is 1:1.

[0020] The sustained-release tablet comprises a diluent and a lubricant.

[0021] Preferably, the diluent is selected from the water-soluble diluent lactose or the water-insoluble diluent microcrystalline cellulose, more preferably microcrystalline cellulose.

[0022] Preferably, the lubricant is selected from magnesium stearate.

[0023] Preferably, the sustained-release tablet comprises the following components and contents:

[0024]

[0025]

[0026] More preferably, the sustained-release tablet comprises the following components and contents:

[0027]

[0028] Further preferably, the sustained-release tablet comprises the following components and contents:

[0029]

[0030] The internal diluent is added during dry granulation; the external diluent is added during the total mixing process.

[0031] The lubricant is added during the total mixing process.

[0032] The sustained-release tablets are prepared by a dry granulation process.

[0033] Another object of the present invention is to provide a method for preparing the sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, comprising the following steps:

[0034] (1) β-nicotinamide mononucleotide and coenzyme Q10 are sequentially passed through a 0.6 mm sieve using a granulator;

[0035] (2) mixing the sieved β-nicotinamide mononucleotide, coenzyme Q10, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and an internal diluent (e.g., internal microcrystalline cellulose) for 10 min at 10 rpm;

[0036] (3) placing the mixed materials in a dry granulator for dry granulation;

[0037] (4) mixing the dry granulated granules with an external diluent (e.g., external microcrystalline cellulose) for 10 min at 10 rpm, and then adding a lubricant and mixing for 5 min at 10 rpm;

[0038] (5) tableting;

[0039] (6) Optional coating.

[0040] Preferably, the dry granulation parameters are as follows: roller speed 10-20 rpm, feed speed 18-30 rpm, roller pressure 25-50 bar, granulation speed 60-120 rpm, granulation screen aperture 1.0 mm.

[0041] The present invention has the following beneficial effects:

[0042] The compound preparation containing β-nicotinamide mononucleotide and coenzyme Q10 of the present invention achieves a broader therapeutic or health-care effect than single preparations.

[0043] The present invention uses different types of hydrophilic gel skeleton materials (hydroxypropyl methylcellulose) to release β-nicotinamide mononucleotide and coenzyme Q10 steadily and achieve a sustained release effect, effectively avoiding fluctuations in blood drug concentrations and peak-valley phenomena.

[0044] The weight ratio of the hydroxypropyl methylcellulose K4MCR to the hydroxypropyl methylcellulose K100LVCR of the present invention is 1:1, and the obtained sustained-release tablet achieves a long-acting release of 24 hours in simulated intestinal fluid (pH 6.8), reduces the use frequency of the medication population, and improves compliance.

[0045] The dry granulation process parameters and production process of the present invention are controllable, and the uniformity between batches and within batches is good; it is simpler than wet granulation and easy to scale up.

[0046] The present invention uses a dry granulation process to prepare a sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, which greatly simplifies the process flow, has good stability, ensures product quality and can reduce the economic burden of users to the greatest extent.

[0047] The sustained-release tablet of the present invention achieves the beneficial effect of long-acting release, reduces the number of medications, and improves the compliance of the user population. The dry granulation product has a short development cycle, simple process, and good preparation reproducibility, which can effectively reduce the medication cost of the user population.

[0048] In summary, the present invention adopts specific components, specific contents, specific dry granulation process, and specific preparation method to obtain sustained-release tablets containing β-nicotinamide mononucleotide and coenzyme Q10, which greatly reduces costs while ensuring the therapeutic effect, significantly reduces the economic burden of patients, and achieves unexpected technical effects. DETAILED DESCRIPTION

[0049] In order to further illustrate the present invention, the sustained-release tablets containing β-nicotinamide mononucleotide and coenzyme Q10 provided by the present invention are described in detail below through examples, but they should not be construed as limiting the scope of protection of the present invention.

[0050] Hydroxypropyl methylcellulose K4MCR, manufacturer: Nutrition&Biosciences USA 1, LLC.

[0051] Hydroxypropyl methylcellulose K100LVCR, manufacturer: Nutrition&Biosciences USA 1, LLC.

[0052] Preparation Example 1: A method for preparing a sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, comprising the following steps:

[0053] (1) Weigh the following materials by weight: 50 parts of β-nicotinamide mononucleotide, 10 parts of coenzyme Q10, 17.2 parts of microcrystalline cellulose, 1.5 parts of magnesium stearate, 10.65 parts of hypromellose K4MCR, and 10.65 parts of hypromellose K100LVCR, of which 6.9 parts of microcrystalline cellulose are used for dry granulation.

[0054] (2) Coenzyme Q10 and β-nicotinamide mononucleotide are sequentially passed through a 0.6 mm sieve using a granulator.

[0055] (3) The sieved coenzyme Q10, β-nicotinamide mononucleotide, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and part of the added microcrystalline cellulose were mixed for 10 min at 10 rpm.

[0056] (4) The mixed materials are placed in a dry granulator for dry granulation. Dry granulation parameters: roller speed 10-20 rpm, feed speed 18-30 rpm, roller pressure 25-50 bar, granulation speed 60-120 rpm, granulation screen aperture 1.0 mm.

[0057] (5) The dry granulated granules were mixed with the externally added microcrystalline cellulose for 10 min at 10 rpm, and magnesium stearate was added and mixed for 5 min at 10 rpm.

[0058] (6) Tableting.

[0059] (7) Coating.

[0060] Preparation Example 2: A method for preparing a sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, comprising the following steps:

[0061] (1) Weigh the following materials by weight: 50 parts of β-nicotinamide mononucleotide, 10 parts of coenzyme Q10, 17.2 parts of microcrystalline cellulose, 1.5 parts of magnesium stearate, 3.55 parts of hypromellose K4MCR, and 17.75 parts of hypromellose K100LVCR, of which 6.9 parts of microcrystalline cellulose are used for dry granulation.

[0062] (2) Coenzyme Q10 and β-nicotinamide mononucleotide are sequentially passed through a 0.6 mm sieve using a granulator.

[0063] (3) The sieved coenzyme Q10, β-nicotinamide mononucleotide, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and part of the added microcrystalline cellulose were mixed for 10 min at 10 rpm.

[0064] (4) The mixed materials are placed in a dry granulator for dry granulation. Dry granulation parameters: roller speed 10-20 rpm, feed speed 18-30 rpm, roller pressure 25-50 bar, granulation speed 60-120 rpm, granulation screen aperture 1.0 mm.

[0065] (5) The dry granulated granules were mixed with the externally added microcrystalline cellulose for 10 min at 10 rpm, and magnesium stearate was added and mixed for 5 min at 10 rpm.

[0066] (6) Tableting.

[0067] (7) Coating.

[0068] Preparation Example 3: A method for preparing a sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, comprising the following steps:

[0069] (1) Weigh the following materials by weight: 50 parts of β-nicotinamide mononucleotide, 10 parts of coenzyme Q10, 17.2 parts of lactose, 1.5 parts of magnesium stearate, 10.65 parts of hypromellose K4MCR, and 10.65 parts of hypromellose K100LVCR, of which 6.9 parts of lactose are incorporated into the dry granulation.

[0070] (2) Coenzyme Q10 and β-nicotinamide mononucleotide are sequentially passed through a 0.6 mm sieve using a granulator.

[0071] (3) The sieved coenzyme Q10, β-nicotinamide mononucleotide, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and part of the lactose were mixed for 10 min at 10 rpm.

[0072] (4) The mixed materials are placed in a dry granulator for dry granulation. Dry granulation parameters: roller speed 10-20 rpm, feed speed 18-30 rpm, roller pressure 25-50 bar, granulation speed 60-120 rpm, granulation screen aperture 1.0 mm.

[0073] (5) The dry granulated granules were mixed with the externally added lactose for 10 min at 10 rpm, and magnesium stearate was added and mixed for 5 min at 10 rpm.

[0074] (6) Tableting.

[0075] (7) Coating.

[0076] Preparation Example 4: A method for preparing a sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, comprising the following steps:

[0077] (1) Weigh the following materials by weight: 50 parts of β-nicotinamide mononucleotide, 10 parts of coenzyme Q10, 18.2 parts of microcrystalline cellulose, 0.5 parts of magnesium stearate, 10.65 parts of hypromellose K4MCR, and 10.65 parts of hypromellose K100LVCR, of which 6.9 parts of microcrystalline cellulose are added for dry granulation.

[0078] (2) Coenzyme Q10 and β-nicotinamide mononucleotide are sequentially passed through a 0.6 mm sieve using a granulator.

[0079] (3) The sieved coenzyme Q10, β-nicotinamide mononucleotide, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and part of the added microcrystalline cellulose were mixed for 10 min at 10 rpm.

[0080] (4) The mixed materials are placed in a dry granulator for dry granulation. Dry granulation parameters: roller speed 10-20 rpm, feed speed 18-30 rpm, roller pressure 25-50 bar, granulation speed 60-120 rpm, granulation screen aperture 1.0 mm.

[0081] (5) The dry granulated granules were mixed with the externally added microcrystalline cellulose for 10 min at 10 rpm, and magnesium stearate was added and mixed for 5 min at 10 rpm.

[0082] (6) Tableting.

[0083] (7) Coating.

[0084] Preparation Example 5: A method for preparing a sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, comprising the following steps:

[0085] (1) Weigh the following materials by weight: 50 parts of β-nicotinamide mononucleotide, 10 parts of coenzyme Q10, 15.7 parts of microcrystalline cellulose, 3.0 parts of magnesium stearate, 10.65 parts of hypromellose K4MCR, and 10.65 parts of hypromellose K100LVCR, of which 6.9 parts of microcrystalline cellulose are used for dry granulation.

[0086] (2) Coenzyme Q10 and β-nicotinamide mononucleotide are sequentially passed through a 0.6 mm sieve using a granulator.

[0087] (3) The sieved coenzyme Q10, β-nicotinamide mononucleotide, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and part of the added microcrystalline cellulose were mixed for 10 min at 10 rpm.

[0088] (4) The mixed materials are placed in a dry granulator for dry granulation. Dry granulation parameters: roller speed 10-20 rpm, feed speed 18-30 rpm, roller pressure 25-50 bar, granulation speed 60-120 rpm, granulation screen aperture 1.0 mm.

[0089] (5) The dry granulated granules were mixed with the externally added microcrystalline cellulose for 10 min at 10 rpm, and magnesium stearate was added and mixed for 5 min at 10 rpm.

[0090] (6) Tableting.

[0091] (7) Coating.

[0092] Experimental Example 1: Comparison of release rates of products with different sustained-release material ratios

[0093] Take the sustained-release tablets containing β-nicotinamide mononucleotide and coenzyme Q10 prepared in Preparation Examples 1 to 2, and refer to the 2020 edition of the "Chinese Pharmacopoeia" to measure the release curve of the above-mentioned sustained-release tablets in simulated intestinal fluid (pH 6.8).

[0094] There is a big difference in the solubility of β-nicotinamide mononucleotide and coenzyme Q10. β-nicotinamide mononucleotide is easily soluble in water, while coenzyme Q10 is very slightly soluble in water. In the sustained-release tablet prepared with hydroxypropyl methylcellulose as the sustained-release material of the present invention, the release of β-nicotinamide mononucleotide is mainly drug diffusion, supplemented by skeleton dissolution; while the release of coenzyme Q10 is mainly skeleton dissolution, and its release degree can be evaluated by the gel dissolution.

[0095] Table 1 Release rate of β-nicotinamide mononucleotide

[0096]

[0097] Table 2 Release of Coenzyme Q10

[0098]

[0099] It can be seen from the release results in Table 1 and Table 2 that the higher the proportion of HPMCR, the slower the release of β-nicotinamide mononucleotide and coenzyme Q10, and the sustained-release tablet of the present invention can maintain a longer release process; when the weight ratio of HPMCR to HPMCR K100LVCR is 1:1, a long-acting release of 24 hours can be achieved, and the frequency of use is once a day; when the weight ratio of HPMCR to HPMCR K100LVCR is 1:5, a long-acting release of 12 hours can be achieved, and the frequency of use is twice a day. Both can effectively reduce the number of medications, improve compliance, and reduce the medication costs of the user population.

[0100] Experimental Example 2: Comparison of release rates of products with different diluents

[0101] Take the sustained-release tablets containing β-nicotinamide mononucleotide and coenzyme Q10 prepared in Preparation Example 1 and Preparation Example 3, and refer to the 2020 edition of the "Chinese Pharmacopoeia" to measure the release curve of the above-mentioned sustained-release tablets in simulated intestinal fluid (pH 6.8).

[0102] Table 3 Release rate of β-nicotinamide mononucleotide

[0103]

[0104] From the release results in Table 3, it can be seen that when the diluent is lactose, the release of β-nicotinamide mononucleotide can be promoted. The reason may be that lactose is a water-soluble material, which can stimulate the penetration of water into the core of the skeleton tablet and accelerate the release of β-nicotinamide mononucleotide. However, the compressibility and fluidity of lactose are not as good as microcrystalline cellulose, and there is a sticking phenomenon during the tableting process. Therefore, microcrystalline cellulose is preferably used as the diluent.

[0105] In addition, experiments have also found that when the external diluent is the water-insoluble auxiliary material microcrystalline cellulose, the smaller the amount used, the faster the release of β-nicotinamide mononucleotide.

[0106] Experimental Example 3: Comparison of the effects of different lubricant concentrations on product release

[0107] Take the sustained-release tablets containing β-nicotinamide mononucleotide and coenzyme Q10 prepared in Preparation Example 1 and Preparation Examples 4 to 5, and refer to the 2020 edition of the "Chinese Pharmacopoeia" to measure the release curve of the above-mentioned sustained-release tablets in simulated intestinal fluid (pH 6.8).

[0108] Table 4 Release rate of β-nicotinamide mononucleotide

[0109]

[0110] From the release results in Table 4, it can be seen that when the amount of magnesium stearate is 3.0%, the release of the sample is significantly slowed down. When the amount of magnesium stearate is 0.5%, there is slight sticking during tableting, while when the amount of magnesium stearate is 1.0%, there is no sticking.

[0111] In summary, the sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10 of the present invention can achieve the beneficial effects of long-acting release of β-nicotinamide mononucleotide and coenzyme Q10, reducing the number of medications and improving medication compliance, and the preparation process of the sustained-release tablet is simple and easy to scale up, which greatly reduces the production cost of the product, thereby achieving the beneficial effect of reducing the medication cost for the user population.

[0112] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the protection scope of the present invention. The protection scope of the present invention should also cover the technical solution and inventive concept of the present invention.

Claims

1. A sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10, characterized in that: The sustained-release material in the sustained-release tablet is a mixture of hypromellose K4MCR and hypromellose K100LVCR; the preparation method adopts dry granulation.

2. The sustained-release tablet according to claim 1, characterized in that The weight ratio of the hypromellose K4MCR to the hypromellose K100LVCR is 1:1 to 1:5; Preferably, the weight ratio of the hypromellose K4MCR to the hypromellose K100LVCR is 1:1 or 1:5; More preferably, the weight ratio of hypromellose K4MCR to hypromellose K100LVCR is 1:

1.

3. The sustained-release tablet according to claim 2, characterized in that The sustained-release tablet comprises a diluent and a lubricant; The diluent is selected from the water-soluble diluent lactose or the water-insoluble diluent microcrystalline cellulose, preferably microcrystalline cellulose; The lubricant is selected from magnesium stearate.

4. The sustained-release tablet according to claim 1, characterized in that The sustained-release tablets contain the following components and contents:

5. The sustained-release tablet according to claim 1, characterized in that The sustained-release tablets contain the following components and contents:

6. The sustained-release tablet according to claim 1, characterized in that The sustained-release tablets contain the following components and contents:

7. The method for preparing the sustained-release tablet containing β-nicotinamide mononucleotide and coenzyme Q10 according to claim 1, comprising the following steps: (1) β-nicotinamide mononucleotide and coenzyme Q10 are sequentially passed through a 0.6 mm sieve using a granulator; (2) Mixing the sieved β-nicotinamide mononucleotide, coenzyme Q10, hydroxypropyl methylcellulose K4MCR, hydroxypropyl methylcellulose K100LVCR, and internal diluent for 10 min at 10 rpm; (3) placing the mixed materials in a dry granulator for dry granulation; (4) Mix the dry granulated granules with the external diluent for 10 min at 10 rpm, add the lubricant and mix for 5 min at 10 rpm; (5) tableting; (6) Optional coating.

8. The preparation method according to claim 7, characterized in that: Dry granulation parameters: roller speed 10-20rpm, feed speed 18-30rpm, roller pressure 25-50bar, granulation speed 60-120rpm, granulation screen aperture 1.0mm.

Citation Information

Patent Citations

  • Nicotinamide mononucleotide sustained-release enteric orally disintegrating tablet and preparation method thereof

    CN112137977A

  • Beta-nicotinamide mononucleotide sustained release tablet

    CN112933058A